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Abstract
Objectives. To investigate whether the therapeutic response of rheumatoid arthritis (RA)
patients to d-penicillamine is associated with polymorphisms in genes of the glutathione
S-transferase (GST) supergene family.
Methods. Disease activity in 81 patients with RA treated with d-penicillamine monotherapy
was assessed using the Stoke Index, a validated index of disease activity, prior to treatment
and at 6 months. GST typing was performed using a polymerase chain reaction-based
approach and a logistic regression model was used to investigate any possible association
between the therapeutic response to d-penicillamine and the GST genotype.
Results. A poor therapeutic response was associated with the GSTM1 null genotype [odds
ratio (OR) 3.94], and in particular with the GSTM1*0/GSTM3*A haplotype (OR 7.63).
Conclusions. Our results suggest that GST polymorphisms may influence the response to
d-penicillamine in RA, and that patients in possession of the GSTM1*0/GSTM3*A haplotype
are significantly less likely to show a beneficial response to the drug.
Key words: d-Pencillamine, Rheumatoid arthritis, Therapeutic response, Glutathione
S-transferase, Polymorphism.
Early and reliable identification of rheumatoid arthritis Although a wide range of drugs, with varying mechan-
isms of action, are available for use in the treatment of(RA) patients who are at risk of poor long-term outcome
would be clinically useful if it allowed more aggressive RA, selection is often problematic because of adverse
reactions or lack of response. Accordingly, drug treat-treatment to be appropriately targeted. There has been
considerable interest, therefore, in the identification of ment in RA is often pragmatic and it is not unusual for
an individual patient to be prescribed a range of diVerentgenetic markers of clinical outcome. Much of this work
has been focused on genes of the HLA system. The drugs during the course of the disease. The identification
of markers that indicate whether or not a particularHLA-DR genotype, and specifically the presence of the
‘RA shared epitope’, a conserved amino acid sequence drug is likely to be beneficial would therefore have
important consequences for treatment.(QKRAA or QRRAA) in positions 70–74 of the DRB1
molecule, has been related to disease severity [1]. It is The enzymes of the cytochrome P450 (CYP) and
glutathione S-transferase (GST) supergene families util-suggested that resistance to drug therapy is a possible
mechanism for this eVect [2], although the influence of ize a wide range of drugs and chemicals as substrates,
suggesting that they may mediate individual responsesHLA status on the response to drugs in RA remains
unclear. Thus, Ten Wolde et al. [3] reported that HLA to drug therapy. There are little data on the influence
of these enzyme families on the metabolism of drugstyping is not helpful in predicting the therapeutic
response to parenteral gold therapy. This is in contrast used to treat RA, although a recent study demonstrated
that the activity of the glucocorticoid-inducible CYP3A4to the reported association of gold toxicity with HLA-
DR3 [4]. There are little data on other genes that might in RA patients was not altered by various anti-rheumatic
agents and substrates of this isoenzyme [5]. GSTinfluence the therapeutic response in RA.
enzymes catalyse the detoxification of a wide range of
electrophiles by catalysing their conjugation withSubmitted 29 January 1998; revised version accepted 2 September
reduced glutathione. They are also believed to play a1998.
Correspondence to: D. L. Mattey. critical role in the detoxification of various endogenous
© 1999 British Society for Rheumatology43








M. A. Layton et al.44
chemicals, including products of oxidant stress such as sent those completing 6 months of d-penicillamine
therapy. The original study group was 86 patients, oflipid and DNA hydroperoxides [6 ]. Polymorphisms
have been identified in genes of the mu (GSTM1, whom four (4.6%) dropped out because of side-eVects
and one (1.2%) was non-compliant. Patients wereGSTM3), theta (GSTT1) and pi (GSTP1) families [7],
and there is evidence that some allelic variants are assessed using the Stoke Index, a validated composite
algorithm designed to give a global measure of diseaseassociated with diVerences in detoxification eYciency.
In several cancers, resistance to chemotherapy has been activity in RA, which is sensitive to response to drug
treatment [13, 15]. The Stoke Index grades diseaseassociated with increased GST activity in tumour cells
[8]. activity on the basis of the Ritchie articular index,
proximal interphangeal joint synovitis (PIP) score, dur-Generation of reactive oxygen species (ROS) is a
marked feature of the inflammatory response in RA, ation of morning stiVness, ESR and CRP. The algorithm
consists of a 17-point scale with 1–3 representing min-and we have suggested that the ability to metabolize
products of ROS may influence long-term outcome. imal disease activity, 4–7 mild, 8–11 moderate and
12–17 severe.Thus, our preliminary data indicate that polymorphisms
in GST genes may have an influence on incidence and In order to determine whether the d-penicillamine-
treated patients represented a typical group of RAdisease outcome in RA [9]. We propose that the ability
to detoxify products of oxidant stress may also influence patients, we also compared the GST frequencies of the
d-penicillamine-treated patients with a much largerthe response to certain drug therapies. In the present
study, we examined the response to d-penicillamine, group of RA patients untreated with this drug
(n= 194), obtained from a study investigating the asso-which has been suggested to act as an antioxidant by
inhibiting lipid peroxidation [10], as well as demonstrat- ciation between GST polymorphisms and disease out-
come [16 ]. There were no significant diVerences betweening hydroxyl radical scavenging activity in vitro [11]. It
has also been shown to increase levels of erythrocyte the two groups for any of the GST genotypes (data
not shown).glutathione in RA patients [12]. We speculate that in
RA patients with certain GST polymorphisms (e.g. Genotype data in the d-penicillamine-treated RA
patients were also compared with those in 577 NorthernGSTM1 null, GSTT1 null, GSTM3AA), there is a
reduced capacity to detoxify the products of oxidative European Caucasians resident in North StaVordshire.
This group comprised 277 men and 300 women with astress produced by the inflammatory process, and that
increased oxidation of d-penicillamine occurs which mean age of 70 yr. Patients with inflammatory path-
ologies such as ulcerative colitis, diabetes or asthmarenders it less eVective. We have tested this view by
investigating the association between GST polymorph- were excluded, although 30% of these controls suVered
diseases including varicose veins, hernias, haemorrhoids,isms and response to treatment as assessed by the Stoke
Index [13]. mild iron deficiency anaemia, mild hyperlipidaemia and
benign ovarian cysts. The remainder suVered tension
headaches (25%), benign skin papillomas (20%), benignPatients and methods
breast lumps (5%), or cerebrovascular accidents (20%).
A study group of 81 patients (38 male, 43 female)
Outcome measuresmeeting the 1987 ACR diagnostic criteria [14] for RA
were selected. The mean age was 52.6 yr (s.d. 9.8) and The therapeutic response at 6 months was defined using
the Stoke Index. Non-responders to therapy werethe mean disease duration 6.1 yr (s.d. 5.8). Of this
group, 48 patients (59.2%) were rheumatoid factor posi- defined as those patients who following 6 months
treatment with d-penicillamine achieved either notive and 13 patients (16%) had rheumatoid nodules. All
patients were unrelated Northern European Caucasians change in their Stoke Index category or entered a worse
category.from North StaVordshire started on d-penicillamine
monotherapy (non-steroidal anti-inflammatory drugs
Genotypingpermitted) on clinical grounds [ 6 painful joints and
erythrocyte sedimentation rate (ESR) >30 mm/h or GST genotypes were identified in leucocyte DNA from
whole blood collected in EDTA. The GSTM1 null, A,C-reactive protein (CRP) >20 mg/l ]. All patients were
assessed prior to therapy and 6 months after starting B and AB genotypes were identified using an amplifica-
tion refractory mutation system (ARMS)-based poly-d-penicillamine according to our standard departmental
clinical protocol. Treatment commenced with 250 mg merase chain reaction (PCR) approach with primer sets
to intron 6/exon 7 and exon 4/exon 5. The assaydaily, increasing at 4 week intervals by increments of
125 mg until either response occurred or the maximum identifies GSTM1*A/GSTM1*B heterozygotes and sub-
jects with the GSTM1 A and GSTM1 B phenotypes. Ittolerated dose was achieved (maximum 750 mg daily).
All patients were advised to take the d-penicillamine as does not distinguish the GSTM1*0/GSTM1*A and
GSTM1*A/GSTM1*A genotypes or the equivalenta single morning dose prior to the intake of food and
there was no concomitant oral iron therapy. Patients GSTM1 B genotypes [17, 18]. The GSTM3 AA, AB
and BB genotypes were identified by amplifying thewere reviewed monthly in our drug monitor clinics in
order to identify any problems of toxicity and monitor exon 6/7 regions of GSTM3*A and GSTM3*B, and
diVerentiating GSTM3*A from GSTM3*B by digestioncompliance with therapy. The 81 patients studied repre-
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with Mnl1 to identify the three-base deletion in intron GSTM1*0/GSTM3*A haplotype was also significantly
higher (OR 7.63, 95% CI 1.84–31.72, P= 0.0052) in the6 of GSTM3*B [19]. The GSTP1 AA, AB and BB
genotypes were identified in leucocyte DNA after PCR non-responders (72.2%) than responders (35.6%),
although no significant eVect of GSTM3 AA alone wasamplification using primers to exon 5 as described by
Harries et al. [20]. The resulting 176 bp fragment was seen. Furthermore, all of the non-responders with the
GSTM1 null genotype were GSTM3 AA positive, whilstdigested with Alw261 to identify the A–G transition as
position 1578 in GSTP1*B. GSTP1*A was refractory to only 70% of the GSTM1 null responders possessed the
GSTM3 AA genotype. There was no significant diVer-digestion whilst GSTP1*B gave fragments of 91 and
85 bp. The GSTT1 null and GSTT1 A expressing sub- ence between the two groups studied in the frequency
of other GST genotypes. No significant correlationjects were also identified using PCR [21].
between GST genotype and rheumatoid factor positivity
Statistical analysis was found.
Logistic regression was used so that any eVect of the
genotype on response could be corrected for age, sex, Discussion
disease duration and initial Stoke Index. There was no
significant diVerence between the responders and the The data presented suggest that RA patients with the
GSTM1 null genotype are significantly more likely thannon-responders for these factors individually, but they
were included in the analysis in the case of a compound patients homo- or heterozygous for the GSTM1*A or
GSTM1*B alleles to respond poorly to d-penicillamineeVect. The odds ratio (OR) was calculated from the
exponential function of the regression coeYcient as during the first 6 months of treatment. Moreover, posses-
sion of the GSTM1*0/GSTM3*A haplotype furtherdescribed by Altman [22]. Estimates of the parameters
associated with the genotype are expressed in terms of increases the likelihood of non-response compared to
patients without this haplotype. The overall GST geno-OR and the associated 95% confidence interval (CI ).
type distribution in the d-penicillamine-treated patients
appears to be representative of the RA patient popula-Results
tion in North StaVordshire since there were no signifi-
cant diVerences in the genotype frequencies of theseEighteen of the 81 patients did not respond to
d-penicillamine at 6 months according to the definition patients and a larger group of RA patients not treated
with the drug.given above. The characteristics of the non-responders
and the responders are summarized in Table 1. There A logistic regression model was used to correct for
the eVect of possible confounding factors such as age,was no significant diVerence in age, disease duration,
rheumatoid factor positivity or Stoke Index prior to gender and disease duration. The analysis does not
exclude the possibility that the eVect is mediated throughtreatment between the two groups. The GST genotype
frequencies in the responders and non-responders are another gene in linkage disequilibrium with GSTM1
and/or GSTM3, or perhaps is due to an unrelated geneshown in Table 2. The frequencies in all the d-penicillam-
ine-treated patients are also reported and compared to encoding a drug-metabolizing enzyme which can be
modulated in association with the GSTM1 null geno-a control group of non-RA patients resident in North
StaVordshire (n= 577). There were no significant type. For example, the GSTM1 null genotype has been
shown to be associated with high inducibility of thediVerences between GST genotype frequencies in the
d-penicillamine-treated RA group and the control cytochrome P450 isoenzyme CYP1A1 [23].
In this study, we have no information on the activitynon-RA group.
Using logistic regression analysis, we found that in d- of other enzyme systems, although the association of
GSTM1 null with a poor response appears to be linkedpenicillamine-treated patients the frequency of GSTM1
null was significantly higher in the non-responders than with the presence of the GSTM3 AA genotype. GSTM3
AA alone was not associated with response. A similarthe responders (72.2% vs 47.6%: OR 3.94, 95% CI
1.07–14.45, P= 0.039). The frequency of the association between these genotypes was found in a
study of patients with multiple basal cell carcinoma,
Table 1. Characteristics of responders and non-responders to where GSTM3 AA alone was not associated with
d-penicillamine increased risk of multiple tumours, but conferred
increased risk in combination with GSTM1 null [24].Non-responders Responders
Co-ordinated expression of the mu class (i.e. GSTM1,n= 18 n= 63
M2, M3, M4, M5) gene cluster on chromosome 1 has(M= 7 F= 11) (M= 31 F= 32)
also been shown in the lung where homozygotes for
Mean age(yr) (s.d.) 52.3 (10.5) 52.9 (9.0) GSTM1*0 express less GSTM3 than subjects with other
Mean disease duration 5.6 (4.2) 6.3 (6.2) GSTM1 genotypes [25]. Although the mechanism for(yr) (s.d.)
this is unclear, it may be related to the finding thatMean age of onset (s.d.) 48.4 (11.8) 47.2 (9.8)
Mean initial Stoke Index 9.5 (2.9) 10.4 (3.4) GSTM3*B is in linkage disequilibrium with GSTM1*A
(s.d.) and contains a recognition motif for the YY1 transcrip-
Mean Stoke Index at 6 8.8 (3.1) 4.3 (2.5) tion factor [26 ], which influences the expression of manymonths (s.d.)
genes. The YY1 recognition motif is absent in
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Table 2. Frequency distribution of GST genotypes in d-penicillamine-treated RA patients compared with non-RA controls
Non-responders Responders All patients Normal controls
Genotype n (%) n (%) n (%) n (%)
GSTM1 null 13 (72.2) 30 (47.6) 43 (53.1) 345 (58.4)
GSTM1A 3 (16.7) 24 (38) 27 (33.3) 152 (25.7)
GSTM1B 2 (11.1) 8 (12.7) 10 (12.3) 72 (12.2)
GSTM1 AB 0 (0) 1 (1.6) 1 (1.2) 22 (3.7)
GSTM3 AA 16 (88.8) 41 (73.2) 57 (77.0) 221 (74.9)
GSTM3 AB 2 (11.1) 14 (25) 16 (21.6) 59 (20)
GSTM3 BB 0 (0) 1 (1.8) 1 (1.4) 15 (5.1)
GSTP1 AA 4 (28.6) 18 (36) 22 (34.4) 136 (45.8)
GSTP1 AB 9 (64.3) 25 (50) 34 (53.1) 118 (39.7)
GSTP1 BB 1 (7.1) 7 (14) 8 (12.5) 43 (14.5)
GSTT1 null 5 (27.7) 14 (22.2) 19 (23.5) 105 (18.9)
GSTT1 A 13 (72.2) 49 (77.8) 62 (76.5) 451 (81.1)
GSTM1*0/GSTM3*A 13 (72.2) 21/59 (35.6) 34/77 (44.2)
GSTM3*A, suggesting that those with either a chemotherapeutic agents in epithelial ovarian cancer
and GSTM1 genotypes. Thus, in women with thisGSTM1*0/GSTM3*A or GSTM1*B/GSTM3*A haplo-
type will express less GSTM3 than those with the cancer, GSTM1 null was associated with a failure to
respond to platinum-based therapy and consequentlyGSTM1*A/GSTM3*B haplotype. Thus, it has been sug-
gested that assessment of the contribution of GSTM1 significantly poorer outcome. Resistance to platinum-
based treatment has been closely associated with cellulargenotypes as susceptibility markers for disease risk needs
to take account of interactions with GSTM3 [18]. The glutathione levels, although it is not known whether our
observations reflect an influence of GST allelic variantsresults of this study now indicate that interactions
between these mu class genes may also be important in on the expression of enzymes involved with glutathione
synthesis [29, 30].determining the response to d-penicillamine.
The mechanism for this eVect is unknown, although Although these mechanisms are purely speculative at
present, the influence of GST polymorphisms in RAwe have speculated that it is related to the apparent
importance of the mu class GST in the detoxification of appear to be important in terms of disease outcome and
the response to d-penicillamine. At present, we do notlipid hydroperoxides, alkenals, DNA hydroperoxides
and other products of oxidative stress. Thus, RA feel that there is suYcient evidence to recommend pre-
treatment genotyping of RA patients in routine clinicalpatients lacking the GSTM1 enzyme and also possessing
lower levels of GSTM3 will have a reduced capacity to practice. More work is required to confirm these finding
and to determine whether the therapeutic response todeal with these potentially cytotoxic chemicals.
Consequently, since d-penicillamine may act as an anti- other disease-modifying anti-rheumatic drugs relates to
the GST genotype.oxidant under some circumstances [10, 11, 27], it is
possible that higher levels of ROS-derived products in
patients with the GSTM1*0/GSTM3*A haplotype result
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